Enfusion Historical Income Statement
| ENFN Stock | USD 11.07 0.11 1.00% |
Historical analysis of Enfusion income statement accounts such as Depreciation And Amortization of 12.1 M or Interest Expense of 2 M can show how well Enfusion performed in making a profits. Evaluating Enfusion income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Enfusion's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Enfusion latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enfusion is a good buy for the upcoming year.
Enfusion |
About Enfusion Income Statement Analysis
Enfusion Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Enfusion shareholders. The income statement also shows Enfusion investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Enfusion Income Statement Chart
Add Fundamental
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most accounts from Enfusion's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Enfusion current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.At this time, Enfusion's EBIT is very stable compared to the past year. As of the 18th of January 2025, Research Development is likely to grow to about 44.2 M, while Tax Provision is likely to drop about 867 K.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Expense | 413K | 1.6M | 1.9M | 2.0M | Depreciation And Amortization | 6.6M | 10.0M | 11.5M | 12.1M |
Enfusion income statement Correlations
Click cells to compare fundamentals
Enfusion Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enfusion income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Tax Provision | 433K | 579K | 1.1M | 1.4M | 1.6M | 867.0K | |
| Net Interest Income | (1.7M) | (4.6M) | 413K | 1.6M | 1.9M | 2.0M | |
| Depreciation And Amortization | 2.3M | 4.0M | 6.6M | 10.0M | 11.5M | 12.1M | |
| Interest Expense | 1.7M | 4.6M | 413K | 1.6M | 1.9M | 2.0M | |
| Selling General Administrative | 35.9M | 150.6M | 68.8M | 64.6M | 74.3M | 74.0M | |
| Selling And Marketing Expenses | 9.9M | 51.7M | 29.3M | 20.4M | 23.5M | 26.1M | |
| Total Revenue | 79.6M | 111.7M | 150.3M | 174.5M | 200.7M | 126.5M | |
| Gross Profit | 58.2M | 79.9M | 103.2M | 116.9M | 134.4M | 88.1M | |
| Other Operating Expenses | 73.5M | 387.6M | 162.3M | 162.6M | 187.0M | 182.8M | |
| Operating Income | 6.1M | (275.9M) | (12.0M) | 11.9M | 10.8M | 11.3M | |
| Net Income From Continuing Ops | 4.1M | (282.2M) | (13.3M) | 9.1M | 8.2M | 8.6M | |
| Ebit | 6.1M | (275.9M) | (12.2M) | 11.9M | 10.8M | 11.3M | |
| Research Development | 6.3M | 153.4M | 17.2M | 19.9M | 22.9M | 44.2M | |
| Ebitda | 8.4M | (271.9M) | (5.6M) | 21.9M | 19.7M | 20.7M | |
| Cost Of Revenue | 21.4M | 31.8M | 47.1M | 57.6M | 66.3M | 38.5M | |
| Total Operating Expenses | 52.1M | 355.7M | 115.2M | 104.9M | 120.7M | 144.4M | |
| Reconciled Depreciation | 2.3M | 4.0M | 6.3M | 8.2M | 9.4M | 4.8M | |
| Income Before Tax | 4.5M | (281.7M) | (12.2M) | 11.5M | 10.3M | 10.9M | |
| Total Other Income Expense Net | (1.6M) | (5.8M) | (225K) | (464K) | (533.6K) | (560.3K) | |
| Net Income | 4.1M | (282.2M) | (13.3M) | 6.0M | 5.4M | 5.7M | |
| Income Tax Expense | 433K | 579K | 1.1M | 2.2M | 2.6M | 2.7M |
Pair Trading with Enfusion
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enfusion will appreciate offsetting losses from the drop in the long position's value.Moving together with Enfusion Stock
| 0.65 | DJCO | Daily Journal Corp | PairCorr |
| 0.82 | AI | C3 Ai Inc | PairCorr |
| 0.84 | AZ | A2Z Smart Technologies | PairCorr |
| 0.67 | BL | Blackline | PairCorr |
Moving against Enfusion Stock
| 0.82 | VERB | VERB TECHNOLOGY PANY | PairCorr |
| 0.81 | VTEX | VTEX | PairCorr |
| 0.54 | ILLRW | Triller Group Symbol Change | PairCorr |
| 0.36 | QH | Quhuo | PairCorr |
The ability to find closely correlated positions to Enfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enfusion to buy it.
The correlation of Enfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enfusion moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.27) | Earnings Share 0.04 | Revenue Per Share | Quarterly Revenue Growth 0.154 | Return On Assets |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.